CD27 Antikörper (PE-Cy5)

Produktnummer ABIN7457292

Dieses Maus Monoklonal-Antikörper erkennt spezifisch CD27 in FACS. Er zeigt eine Reaktivität gegenüber Human.

Kurzübersicht für CD27 Antikörper (PE-Cy5) (ABIN7457292)

Target: CD27 (CD27 Molecule (CD27))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser CD27 Antikörper ist konjugiert mit PE-Cy5

Applikation: Flow Cytometry (FACS)

Klon: O323

Produktdetails anti-CD27 Antikörper (PE-Cy5)

Isotyp: IgG1, kappa

Anwendungsinformationen

Applikationshinweise: The amount of the reagent is suggested to be used 5 µL of antibody per test (million cells in 100 µL staining volume or per 100 µL of whole blood). Check your vial before the experiment. Since applications vary, the appropriate dilutions must be determined for individual use.

Kommentare:

Matching Isotype Control: PE/Cyanine5 Mouse IgG1, κ Isotype Control

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Buffer: PBS with 0.05 % Proclin300, 1 % BSA

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C

Informationen zur Lagerung: Store at 2~8°C and protected from prolonged exposure to light. Do not freeze.

Details zu CD27

Target: CD27 (CD27 Molecule (CD27))

Andere Bezeichnung: CD27

Hintergrund: CD27L receptor,T-cell activation antigen CD27,T14,S152,TNFRSF7,CD27 is a 50-55 kD type I membrane protein also known as S152 and T14. It is a lymphocyte-specific member of the TNF-receptor superfamily. CD27 is expressed on medullary thymocytes, virtually all mature T cells, some B cells, and NK cells. CD27 binds to CD70 and plays an important role in costimulation of T cell activation, and regulation of B cell differentiation and proliferation. The cytoplasmic domains of CD27 have also been shown to interact with TRAF2 and TRAF5 to elicit NF-κB and SAPK/JNK activation.

Gen-ID: 939

UniProt: P26842

Pathways: Production of Molecular Mediator of Immune Response, Cancer Immune Checkpoints